MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...
We highlight our top five stories of 2025 based on popularity; included are a special report on reshoring, a commentary on grid inertia, and a utility case study on substations... As electrification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback